Is VOD a big enough antithrombin market to justify GTC/Leo’s pursuing an indication? Or would it be more practical to do nothing and hope for a modicum of off-label sales? T.i.a. Dew
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”